Form 4: Neurogene CFO Sells Shares for Tax Obligations

Neurogene Inc.'s President and CFO, Christine Mikail Cvijic, sold 2,558 shares of common stock at a weighted average price of $21.6247 to cover tax withholding obligations from a restricted stock unit vesting.

Summary

• Christine Mikail Cvijic, President and CFO of Neurogene Inc. (NGNE), reported a sale of 2,558 shares of common stock.
• The transaction occurred on March 26, 2026, at a weighted average price of $21.6247 per share.
• This sale was mandatory, executed to cover tax withholding responsibilities arising from the partial vesting of a Restricted Stock Unit (RSU) award, with no election made by the Reporting Person.
• Following this transaction, Ms. Cvijic beneficially owns 103,240 shares directly.
• Remaining beneficial ownership includes 10,635 restricted stock units granted on March 13, 2024, that will vest on March 13, 2027.
• Additionally, 13,533 restricted stock units granted on March 26, 2025, will vest annually in equal installments on March 26, 2027, and March 26, 2028.
• Furthermore, 22,000 restricted stock units granted on February 20, 2026, will vest annually in equal installments on February 20, 2027, February 20, 2028, and February 20, 2029.
• Of the remaining shares, 19,200 are held jointly by Ms. Cvijic and her spouse, David Cvijic.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. While it involves a sale of shares, it is a non-discretionary transaction stemming from the vesting of executive compensation, indicating value realization and continued long-term equity alignment.

Positives

• The underlying event is the vesting of Restricted Stock Units, indicating compensation realization for the executive and value creation.
• The sale was non-discretionary and solely for tax withholding purposes, not a voluntary divestment of shares.
• Ms. Cvijic retains a significant beneficial ownership of 103,240 shares, including substantial unvested RSUs, demonstrating continued alignment with shareholder interests.

Negatives

• A reduction in direct share ownership by a key executive, albeit for tax purposes.

Future Outlook

The filing indicates future vesting schedules for various restricted stock unit grants, with vesting dates extending through February 2029, suggesting continued long-term incentive alignment for the executive.

Management Comments

• The sale relates exclusively to a mandatory sale upon vesting of a Restricted Stock Unit (RSU) to cover the Reporting Person's tax withholding responsibility, with no election made by the Reporting Person.

Industry Context

StockSavvy.ai notes that mandatory sales of shares to cover tax obligations upon the vesting of restricted stock units are a common and routine occurrence in executive compensation across various industries. This transaction is typical for executives receiving equity-based compensation.

Comparison to Industry Standards

• The mechanism of selling shares to cover tax withholding upon RSU vesting is a standard practice in executive compensation plans across publicly traded companies, aligning with common industry benchmarks for equity compensation management.
• The reported sale price range ($21.10 to $21.91) is consistent with market-based transactions for Neurogene Inc. common stock on the transaction date, similar to how other companies' executives execute such sales.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is a small, mandatory transaction for tax purposes, not a discretionary divestment. The executive maintains significant equity holdings, aligning interests.
• Employees: No direct impact mentioned.

Next Steps

• Vesting of 10,635 restricted stock units on March 13, 2027.
• First annual vesting installment for 13,533 restricted stock units on March 26, 2027.
• First annual vesting installment for 22,000 restricted stock units on February 20, 2027.
• Second annual vesting installment for 13,533 restricted stock units on March 26, 2028.
• Second annual vesting installment for 22,000 restricted stock units on February 20, 2028.
• Third annual vesting installment for 22,000 restricted stock units on February 20, 2029.

Key Dates

Recommendation

This Form 4 details a routine, mandatory sale of shares by an executive to cover tax obligations upon RSU vesting. It does not indicate any change in the company's fundamentals or strategic direction, nor does it suggest a discretionary move by the insider to significantly alter their stake. Therefore, a 'hold' recommendation is appropriate as this transaction alone does not provide a strong signal for a buy or sell decision.

Keywords

Neurogene, NGNE, Form 4, Insider Transaction, Stock Sale, Restricted Stock Unit, RSU, Tax Withholding, Executive Compensation